Clinical Trial

A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
\[Phase I part\] To investigate the safety, tolerability, and pharmacokinetics of MT-2111 monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). In addition, the dose to be used in the Phase II part will be confirmed. \[Phase II part\] To evaluate the efficacy of MT-2111 monotherapy in patients with relapsed/refractory DLBCL. In addition, the safety and pharmacokinetics will be investigated.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2022-12-13; most recent amendment 2026-06-08.
Status change: Recruiting → Active, Not Recruiting 2025-07-04
Status change: Not Yet Recruiting → Recruiting 2023-01-12
Trial Details
NCT Number NCT05658562
Lead Sponsor Tanabe Pharma Corporation
Conditions Diffuse Large B-Cell Lymphoma
Enrollment 46 participants
Start Date 2023-01-30
Primary Completion 2028-08 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-09